Alnylam Pharmaceuticals Inc
ALNY: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$189.00 | Sqjwd | Knkvcnsrq |
Narrow-Moat Alnylam Reports Q4 Results Within Our Expectations; Maintaining $158 FVE
Alnylam reported solid fourth-quarter results largely within our expectations. 2021 net product revenue was $662 million, representing an 83% increase from the prior year as the company continues to expand its commercialization efforts globally. We maintain our $158 fair value estimate and view shares as currently fairly valued.